Scholarlink

<p>Agitation and psychosis are common, highly challenging symptoms of Alzheimer’s disease (AD). Although non-pharmacological strategies are the recommended first-line treatment for agitation and psychosis in AD, pharmacological interventions may be necessary if there is severe risk of self-harm or harm to others. Brexpiprazole is approved by the US FDA for treatment of agitation associated with dementia due to AD, while other medications are used off label. Several novel and repurposed drugs are under investigation for use in agitation and psychosis in AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Consider brexpiprazole for agitation in Alzheimer’s disease, with new therapies under investigation for agitation and psychosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Thomas B. Burgess,
  • Simon Fung

摘要

Agitation and psychosis are common, highly challenging symptoms of Alzheimer’s disease (AD). Although non-pharmacological strategies are the recommended first-line treatment for agitation and psychosis in AD, pharmacological interventions may be necessary if there is severe risk of self-harm or harm to others. Brexpiprazole is approved by the US FDA for treatment of agitation associated with dementia due to AD, while other medications are used off label. Several novel and repurposed drugs are under investigation for use in agitation and psychosis in AD.